Immunotherapy is changing the way the medical community thinks about treating cancer. Brad Loncar, CEO of Loncar Investments, said Wall Street needs to follow suit and change the way it invests in cancer drug companies. ‘This is a high growth area within biotech,’ said Loncar. ‘Investors should not think of biotech as one thing, it is made up of many different things.’ Immunotherapy is a treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done by stimulating the patient’s immune system to work harder or smarter to attack cancer cells, or giving his or her immune system components, such as man-made immune system proteins. The alternative to immunotherapy is chemotherapy, which Loncar calls ‘toxic to the whole body.’ Immunotherapy, on the other hand, is natural and might produce more powerful and longer lasting responses. Loncar, who is donating a portion of the profits from this to Cancer Research Institute, launched the Loncar Cancer Immunotherapy ETF (CNCR) in October because, in his opinion, the other biotech indices are ‘too broad.’ Holdings in the CNCR include large companies including Bristol-Myers (BMY) and Merck (MRK).
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
